TC Biopharm (Holdings) Plc (TCBP)

Market Cap	1.57M
Revenue (ttm)	n/a
Net Income (ttm)	-7.48M
Shares Out	1.03M
EPS (ttm)	-23.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,238
Open	1.550
Previous Close	1.570
Day's Range	1.540 - 1.670
52-Week Range	0.850 - 320.000
Beta	0.33
Analysts	Strong Buy
Price Target	1,400.00 (+86,319.75%)
Earnings Date	May 7, 2024

About TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 11, 2022
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: TCBP

Financial Performance

Financial numbers in GBP

Analyst Forecast

According to one analyst, the rating for TCBP stock is "Strong Buy" and the 12-month stock price forecast is $1,400.0.

Price Target

$1,400.0

(86,319.75% upside)

Analyst Consensus: Strong Buy